{"name":"Regeneron Pharmaceuticals","slug":"regeneron-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5872227000,"revenueGrowth":291.3,"grossMargin":0,"rdSpend":5850200000,"netIncome":4504900000,"cash":3118100000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[{"name":"Libtayo","genericName":"CEMIPLIMAB","slug":"cemiplimab","revenue":1452000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2018-01-01","label":"Libtayo first approved","drug":"Libtayo","drugSlug":"cemiplimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"IMDEVIMAB first approved","drug":"IMDEVIMAB","drugSlug":"imdevimab","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Ronapreve first approved","drug":"Ronapreve","drugSlug":"casirivimab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":1452000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Libtayo","genericName":"CEMIPLIMAB","slug":"cemiplimab","indication":"Malignant tumor of cervix","status":"marketed","revenue":1452000000}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"ALN-SNCA","genericName":"ALN-SNCA","slug":"aln-snca","indication":"Other","status":"phase_1"},{"name":"Apixiban","genericName":"Apixiban","slug":"apixiban","indication":"Other","status":"phase_2"},{"name":"Fasinumab AI","genericName":"Fasinumab AI","slug":"fasinumab-ai","indication":"Other","status":"phase_1"},{"name":"Noninterventional","genericName":"Noninterventional","slug":"noninterventional","indication":"Other","status":"phase_2"},{"name":"REGN5837","genericName":"REGN5837","slug":"regn5837","indication":"Other","status":"phase_1"},{"name":"VEOPOZ","genericName":"POZELIMAB-BBFG","slug":"pozelimab-bbfg","indication":"CD55-deficient PLE (CHAPLE disease)","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"EVKEEZA","genericName":"EVINACUMAB-DGNB","slug":"evinacumab-dgnb","indication":"Homozygous familial hypercholesterolemia","status":"marketed"},{"name":"Praluent","genericName":"Praluent","slug":"praluent","indication":"Atherosclerosis","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"IMDEVIMAB","genericName":"IMDEVIMAB","slug":"imdevimab","indication":"COVID-19","status":"discontinued"},{"name":"Ronapreve","genericName":"CASIRIVIMAB","slug":"casirivimab","indication":"COVID-19","status":"marketed"}]}],"pipeline":[{"name":"Libtayo","genericName":"CEMIPLIMAB","slug":"cemiplimab","phase":"marketed","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.","indications":["Malignant tumor of cervix","Metastatic basal cell carcinoma","Non-small cell lung cancer without mutation in epidermal growth factor receptor","Nonsmall cell lung cancer without mutation in epidermal growth factor receptor","Squamous cell carcinoma"],"catalyst":""},{"name":"ALN-SNCA","genericName":"ALN-SNCA","slug":"aln-snca","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Apixiban","genericName":"Apixiban","slug":"apixiban","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EVKEEZA","genericName":"EVINACUMAB-DGNB","slug":"evinacumab-dgnb","phase":"marketed","mechanism":"Angiopoietin-related protein 3","indications":["Homozygous familial hypercholesterolemia"],"catalyst":""},{"name":"Fasinumab AI","genericName":"Fasinumab AI","slug":"fasinumab-ai","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IMDEVIMAB","genericName":"IMDEVIMAB","slug":"imdevimab","phase":"discontinued","mechanism":"IMDEVIMAB works by binding to the SARS-CoV-2 virus to prevent it from entering host cells.","indications":["COVID-19"],"catalyst":""},{"name":"Noninterventional","genericName":"Noninterventional","slug":"noninterventional","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Praluent","genericName":"Praluent","slug":"praluent","phase":"marketed","mechanism":"Proprotein convertase subtilisin/kexin type 9","indications":["Atherosclerosis","Complex dyslipidemia","Familial hypercholesterolemia - heterozygous","Hypercholesterolemia"],"catalyst":""},{"name":"REGN5837","genericName":"REGN5837","slug":"regn5837","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ronapreve","genericName":"CASIRIVIMAB","slug":"casirivimab","phase":"marketed","mechanism":"Monoclonal antibody","indications":["COVID-19"],"catalyst":""},{"name":"VEOPOZ","genericName":"POZELIMAB-BBFG","slug":"pozelimab-bbfg","phase":"marketed","mechanism":"Pozelimab-bbfg blocks C5 cleavage, preventing C5a and C5b formation and inhibiting terminal complement activation.","indications":["CD55-deficient PLE (CHAPLE disease)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdkhkdnpoYnBoTE9zSXZxeFFvM0dxT053bnQyMENyekwtX3hxbHFFV1l0Y2lGX09BNDhoQlNvc2VMRnFVUTFuaEo4X1VBbHBfZlhYX3prRWgyb1h2VTluVDN0S3dLVnJJTXNQc1J1ZHdIR24tajZ3N1QzWElwMGhvRlA4akNxa19VS0tDM1BDLVBxZDZZZFJYY0VQRi00SVlmbDBmcG1LM1ZGQndPbng3Yi1mVVh3aENYOFhxS19yaUhKYm8?oc=5","date":"2026-04-02","type":"pipeline","source":"Reuters","summary":"Regeneron says it expects to avoid new US pharma tariffs - Reuters","headline":"Regeneron says it expects to avoid new US pharma tariffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNN2dPM0lvTWhPZlZGSUlYaExucjg5NEJza2I4YXA0UktJaS1RaW03a2ZPbHJJdXhDamlXWGtoa2xPc3cyS1NBcXJ4a0MxMEVBX09FYXR3YVBsQ0t3SVBNYjB3WWFISnp4QldXSGRrQ0FKUVpIeExaMjdMRU84ODdtdWlpNzVRcmg0b3NQYjBBWXNUOS03c1k2OHFJNFpDTXhwdjBhS3RRaTEtODhVM3gzMVZpNVZ6ZlBXTUNWNXp1YkZVd1VYQThMcDVWZmtxY0Q0SS1XMVJWZTMzMXFaRXZxVFlBdmZ4SlQxY2J2Y0ZHUE5KdUI1VDdIMlpSZ1QxTnFpVzE2Wnd4VEFwZjBqNE9SS2tfcEk0Qk41LUdmempZaVRrUjZzMkh3VUlLUVY0Qkd4cmdSY0hYVExJaGV5dW9Ndk9qdWpkVjVWaHROLVM1ZkFENGI5Ymc?oc=5","date":"2026-04-02","type":"pipeline","source":"msn.com","summary":"Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock - msn.com","headline":"Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNSkt2TzVEOHJvTmlRQkl1cXdybEVnT0hGN0pZQ0EzblJoY0N4SUN2NGM0NUI2ZmNwUXJzaXdoMzVfT3RxUzNLVWpBVHRFRlNDU0htRFIzWmZ1UUZEU3kyN2VBTjBZTTh3bTgxaVVOZk1ZT1VYOENHSHc2eGc4YXhqUndENmZHSll5blRZSEZDN2R1Z1BLV3J6OUJfN0hTYzN5bFBZ?oc=5","date":"2026-03-30","type":"pipeline","source":"Yahoo Finance","summary":"Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock - Yahoo Finance","headline":"Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQaUxWTVQ1OUNCdlVidEx5b21jYUxTdVFZZEl4dlBSQ05rOE8teVhwZHJrcEp3ZGZheklhem9QdlgwbGZuUEF0a0M5SFdLaDRDYnJyQ2xSSEJSMDZCVzFvQ09fYmJTV05VUkxQekVSdVRBWG13LUpwV0RFTlA3RTdSazdyaXQ?oc=5","date":"2026-03-25","type":"earnings","source":"Statista","summary":"Revenue of Regeneron Pharmaceuticals from 2021 to 2025 - Statista","headline":"Revenue of Regeneron Pharmaceuticals from 2021 to 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPbEh4X0psN0hVR2ItNnBRM0RwVmUzc0VHVW01X3d2ZGRyUy1tZlZCMGJrdzNtTk4xREgtazB6akRWbFV5d0tHcHdaWkJ2TlZNTGloUS1YREkwMXR3cnRYSGd5bkhCNEhrelRiNkZvT0RMVVNpMVVGOXRpWUxXRHZMNzVoQkY5VGl3X3A1UzBLdlNOd19FcWE1bQ?oc=5","date":"2026-03-09","type":"trial","source":"Fierce Biotech","summary":"Regeneron's obesity drug shows Zepbound-like efficacy in phase 3 - Fierce Biotech","headline":"Regeneron's obesity drug shows Zepbound-like efficacy in phase 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNLUFjYTB2MDROdFBRcm5PaG9UMGw4bkZ1a0F0Y2U4V3pDZDlLNkIzcmdvMWhTUEJSUDVUZXE1UTBhYmtJR0JDVEltdmJ0TGtEMWh5eFJjLTUwTWt5SlBqcDFLeG5NREZFeVpiSmVZS0FBZGtVT2daR04xMGJXYWIzck44THdfcFItbmFsMUJLUmRsTUFja0E?oc=5","date":"2026-02-27","type":"pipeline","source":"Seeking Alpha","summary":"Why Dupixent Keeps Regeneron A Top Big Pharma Pick - Seeking Alpha","headline":"Why Dupixent Keeps Regeneron A Top Big Pharma Pick","sentiment":"neutral"},{"date":"2026-02-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPREM4Zm5LQmlSRTNDRl9qd0FQR3c1TlJ3QlF4RFFBeG11YTRxUzI4OGNFM0tJRFUwTFYycWFyQ0xrNnRzY3lCdjlxd1BBQllTQ2QwdzZYTjV0UUlLVy1Hc2ZvNEVFTjlySEJlYlUyekZOa3NaMVFiSGFITVktS2IyVy1oZmxPOGpNcmhCak5ITGVFa0NaUGRxT01CbkpVTjJBcEE?oc=5","date":"2026-01-30","type":"earnings","source":"Fierce Pharma","summary":"A sales turnaround for Regeneron's Eylea franchise will have to wait at least another quarter - Fierce Pharma","headline":"A sales turnaround for Regeneron's Eylea franchise will have to wait at least another quarter","sentiment":"neutral"},{"date":"2026-01-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE92QVdyRmN3MGlwa2s0d3NKQWVZa2ZHd3RYNklaZXRJd1RWYVpEZXM3Rng5VmtSQl90LXlGYUNVQ3EzNkNDekJrZURpM0ZSaWFUZTBjd2VKZV9JNnJ5aVpSdGZJTFR2dlQ3Q25GbEdGYXA?oc=5","date":"2026-01-07","type":"deal","source":"Barron's","summary":"Regeneron Stock Lagged Behind the S&P 500 Last Year. Why It’s a Buy Anyway. - Barron's","headline":"Regeneron Stock Lagged Behind the S&P 500 Last Year. Why It’s a Buy Anyway. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNbTFRS2V0Q0FDcXpCY051bmpTV2IzWnFnY0E1ZVF4UzlxaFhFOXRQdldzWEw1WlhSeHpaVW8zU1RtdVFzd1NYN2JHXy12dWdFUVplRWpBT2Rmdmh2X2ZJVEFET2RnNmlzWHNxaVBTLWZTdUplSW9reXo2bUFvNTktMEtFX24wT2VSRDBCQWN1NFZwZlFnUFVfbDJmQlBkTUpxWVV1Vk1ueU5uUQ?oc=5","date":"2025-10-09","type":"pipeline","source":"BioPharma Dive","summary":"Regeneron, needing a turnaround, gains new use for cancer drug - BioPharma Dive","headline":"Regeneron, needing a turnaround, gains new use for cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOYVFhU2g2MjJGQWo5ZjZCZGlyNGIwR01XS2lDZ2pFYWVnM1FqM2FDLTUzV19HYVBFU2VraFBmclNqeWw3U2V1X0t0TnJ4OE1Zdlk5Ukh6UmZJd3YxMUJUVm4xV1lpVkZxaFVpUFpla1htdlhzNVc2anFCNjdfVDZ3alVaWWdrVzZYVHpjd0IyRzBDSXk0Snh3S1VBV21WNFFJU0tXdW9haUtUMXEteTFYZWd3V3dsWFNmR1VzR2pZX2drQkQyVjJXUWNyQnFZTjkw?oc=5","date":"2025-10-08","type":"pipeline","source":"Investing.com","summary":"Regeneron Pharma stock price target raised by RBC to $704 on Dupixent growth - Investing.com","headline":"Regeneron Pharma stock price target raised by RBC to $704 on Dupixent growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOd0ViRmdvdFdoamxmSEhWd3dkUXljMUFjZXpFaGVJV2tKTmRqaEJDeTU0QS1kYlhpRG4tVnJEd3dsWmY0R2hJTnVEMFJObkJpQWZscm13bW00RGJvRkhnNVM4UEdCVUVpSFBycE1pNzF6bENyendtOGt4eW9BZmpFNDZNYkd6cWxrbHNXd1dOMERGVVIyNHJQM0c5VjdINk5HdVViS1V5UFLSAa4BQVVfeXFMTU91T3FvcUJ0MllqSzRYaXpXUWtqYV9JNTRVSlR0RW1IblhmNXRpQTItNmpqWHg3U29JNm1nNVktRXpZX010a21VaDIwVDBmUWdBeXFZMTlmWEU5NGozLXF3SmpVWWVBQVlRT3Q4dEtQU3gxSkE5aUxmMWRpc0ZrQzZBZWxza1RnbnZWNmRPNGVYQ0RkaVJPR0JmYUF3anpDd1FCTGs1VjFKN29EOXhB?oc=5","date":"2025-08-21","type":"pipeline","source":"CNBC","summary":"A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs - CNBC","headline":"A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"marketed":5,"phase_1":3,"phase_2":2,"discontinued":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":5872227000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":5872227000,"period":"2017-12-31"},{"value":1500673000,"period":"2017-09-30"},{"value":1470116000,"period":"2017-06-30"},{"value":1318991000,"period":"2017-03-31"},{"value":4860427000,"period":"2016-12-31"},{"value":1220122000,"period":"2016-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5850200000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":4504900000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":3118100000,"cashHistory":[],"totalAssets":40558700000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}